Published in Cancer Weekly, September 28th, 2004
Oncologists in the Netherlands conducted a "study of liposome encapsulated paclitaxel (LEP)" to "define the maximum-tolerated dose (MTD), the recommended dose (RD), the dose-limiting toxicities (DLTs), the pharmacokinetic profiles, and to evaluate preliminarily antitumor effects in patients with refractory solid malignancies."
"LEP was administered as an intravenous (i.v.) infusion over 45 min once every week for 6 out of 8 weeks," explained O. Soepenberg and coauthors at Erasmus Medical Centre in Rotterdam. "Fourteen patients were treated at doses ranging...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.